Tuesday, May 7
3:30PM - 4:30PM
Core/Medical Track

Concurrent Session 6.3:
Charting New Frontiers: Cancer Breakthroughs and Their Impact

A number of advances in cancer prevention, diagnosis, and treatment have been making headlines in recent years, but how much is hype and how much is hope? Will there be a meaningful shift in the mortality from cancer, the leading cause of death in most insurance portfolios, and how will these advances impact underwriting?

Dr. Brad Heltemes, MD, DBIM, FAAIM, VP and Medical Director R&D, Munich Re